Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79687 | 0.91 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3608660 | 0.91 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL29783525 | 0.91 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14338819 | 0.90 | MAPK1 (0.36) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL7831913 | 0.89 | CRHR1 (0.36) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL976390 | 0.89 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL80486 | 0.89 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3117730 | 0.89 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL22637997 | 0.89 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL343322 | 0.89 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | claimed |
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | claimed |
| EP-0975634-B1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2001-07-04 | — | — | EP | claimed |
| US-8974806-B2 | Method for producing aqueous active substance compositions of active substances that are hardly soluble in water | BASF AKTIENGESELLSCHAFT (DE) | 2015-03-10 | — | — | US | disclosed |
| US-8728504-B2 | Process for solubilizing hydrophobic active ingredients in aqueous medium | BASF SE (DE) | 2014-05-20 | — | — | US | disclosed |
| EP-2676680-A1 | Use of hydrophobin polypeptides as penetration enhancers | BASF SE (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8497230-B2 | Solid crop protection agents containing polyalkoxylate, method for their production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20130123108-A1 | ACTIVE SUBSTANCE COMPOSITION COMPRISING AT LEAST ONE NITROGEN ATOM-CONTAINING, HYPERBRANCHED POLYMER | BASF SE (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-1763300-B1 | USE OF ETHER GROUP-CONTAINING POLYMERS AS SOLUBILIZERS | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20110312497-A1 | USE OF HYDROPHOBIN AS A SPREADING AGENT | BASF SE (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2006087227-A2 | ACTIVE SUBSTANCE COMPOSITION COMPRISING AT LEAST ONE NITROGEN ATOM-CONTAINING, HYPERBRANCHED POLYMER | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006015791-A2 | METHOD FOR PRODUCING AQUEOUS ACTIVE SUBSTANCE COMPOSITIONS OF ACTIVE SUBSTANCES THAT ARE HARDLY SOLUBLE IN WATER | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6297251-B1 | Fungicidal trifluorophenyl-triazolopyrimidines | AMERICAN CYANAMID CO. | 2001-10-02 | — | — | US | disclosed |
| EP-0975634-B1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6117876-A | Fungicidal trifluorophenyl-triazolopyrimidines | AMERICAN CYANAMID COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0975634-A1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046607-A1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | MAPK1 916/4885KMT2A 2012/4885MEN1 2807/4885 |
| US-20110312497-A1 | USE OF HYDROPHOBIN AS A SPREADING AGENT | PFN1, DSTN, CHN2 | MAPK1 3589/4885KMT2A 4413/4885MEN1 958/4885 |
| US-20130123108-A1 | ACTIVE SUBSTANCE COMPOSITION COMPRISING AT LEAST ONE NITROGEN ATOM-CONTAINING, HYPERBRANCHED POLYMER | NOS1, NOS3, NPSR1 | MAPK1 2382/4885KMT2A 3704/4885MEN1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.